




XIX ENCONTRO GALEGO-PORTUGUÉS DE QUÍMICA



VIGO - ESPAÑA
2013

XIX ENCONTRO GALEGO-PORTUGUÉS DE QUÍMICA
Noviembre 2013

Coordinador Editorial
Antonio Macho Senra

Edita
Colegio Oficial de Químicos de Galicia
Rúa Urzaiz, 1 – 2º dcha.
36201 Vigo (Pontevedra)
www.colquiga.org

Tirada
250 Ejemplares

Imprime
ROCARPE Impresores, S.L.

Depósito Legal
VG 739-2013

ISBN
978-84-695-8688-4

Este libro de comunicaciones y conferencias, presentadas en el XIX Encontro Galego-Portugués de Química, ha sido editado con el patrocinio de la Diputación Provincial de Pontevedra.

Catalogación recomendada
Libro de resúmenes del XIX Encontro Galego-Portugués de Química
Museo do Mar de Galicia. Vigo (España), 2013

© Colegio Oficial de Químicos de Galicia

Derechos reservados. Prohibida la reproducción de este libro por cualquier medio, total o parcialmente, sin permiso expreso del editor.

Virtual screening of thieno[3,2-*b*]pyridine arylthioether (hetero)aryltriazole derivatives as potential tyrosine kinase VEGFR2 inhibitors

Ricardo C. Calhella^{1,2}, Agathe Begouin², Joana F. Campos²,
Isabel C.F.R. Ferreira¹, Maria-João R.P. Queiroz², Rui M.V. Abreu¹

1) Centro de Investigação de Montanha (CIMO), ESA, Instituto Politécnico de Bragança, Campus de Sta. Apolónia, Apartado 1172, 5301-855 Bragança, Portugal

2) Centro de Química, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal

Recently we presented a series of thieno[3,2-*d*]pyrimidine ether 1,3-diaryl ureas with potent VEGFR2 inhibition activity. The binding mode was analyzed and the compounds showed a type-II tyrosine kinase inhibition mode, with the thienopyrimidine moiety forming a Hydrogen Bond (H-bond) with CYS919 residue and the urea moiety forming H-bonds with key residues GLU885 and ASP1046 of the kinase domain.¹

In this study, the potential of changing the more widely used urea moiety to a triazole moiety now in thieno[3,2-*b*]pyridine arylthioethers, was analyzed. A number of 3D thieno[3,2-*b*]pyridine arylthioethers (hetero)aryltriazole derivatives (Figure 1) were designed and then molecular docking studies, using AutoDock4, were performed against a VEGFR2 crystal




Figure 1. a) General structure of the thieno[3,2-*b*]pyridine thioether triazole derivatives designed in the present study; b) Docking binding mode of the most potent thieno[3,2-*b*]pyridine triazole derivative (cyan), with the predicted H-bond shown in red. For comparison, the co-crystallized inhibitor of the VEGFR2 structure (PDB:3VHE) is presented (green lines), with the respective H-bonds in yellow.

The structures and docking poses obtained for thieno[3,2-*b*]pyridine thioether triazole derivatives are present. Results show that the triazole moiety may be able to replace the urea moiety and form similar H-bonds. The thieno[3,2-*b*]pyridine thioether aryltriazole derivatives with F or Br in the *para* position, respectively, present the lowest predicted binding energy (ΔG). Due to the potential to inhibit VEGFR2, these compounds were synthesized and then tested in enzymatic, cellular and biomolecular assays.

Acknowledgements: Foundation for the Science and Technology (FCT–Portugal) through the Portuguese NMR network, FCT and FEDER (European Fund for Regional Development)-COMPETE/OREN/EU for financial support through the research unities PEst-C/QUI/UI686/2011 and PEst-OE/AG7/410660/2011, the research project PTDC/QUI-QUI/111060/2009 and the post-Doctoral grants attributed to R.C.C. (SFRH/BPD/68344/2010) and A.B. (SFRH/BPD/36753/2007) also financed by the POPH and FSE.

Reference

(1) M.-J. Queiroz, *et al. BioMed Res. Int.* **2013**, *2013*, 1-9.



Museo do Mar de Galicia
13 al 15 de noviembre de 2013
Vigo - España

D. Ricardo C. Calhelha, ha participado en el *XIX Encontro Galego-Portugués de Química* celebrado, en el Salón de Actos del Museo do Mar de Galicia (Vigo - España), del 13 al 15 de noviembre de 2013, presentando la comunicación "*Virtual screening of thieno[3,2-b]pyridine arylthioether (hetero)aryltriazole derivatives as potential tyrosine kinase VEGFR2 inhibitors*"

En Vigo, a 13 de noviembre de 2013




Rafael Rubido Muñiz
Coordinador Comisión Organizadora

